Keyword Submission Number(s)

16p11.2 T81

17-β-estradiol M166

1H MRS 30.2, T122

1H-MRS W45, W128

25CN-NBOH W200

31P magnetic resonance spectroscopy 54

3D genome 25.3

5-HT1A receptors M98

7-dehydrocholesterol T117

7T T69

ABCD study 55, W31

Abstinence T41, T55

Abuse Liability M175, T149

Abuse potential M139, T157, W150

Acamprosate W23

Accelerated aging T10, W130

Acetylcholine 14.2

Acetylcholine esterase inhibitors T150

acoustic startle response 14.4, M75, T91

Actigraphy W43

Activated microglia 43, 43.5

Activity-regulated cytoskeleton-associated protein W55

Acute effects T168, W174

Acute stress 28.1, 34.2, M43, W14

Acute traumatic stress M5

Adaptive behavior M16

Adaptive deep brain stimulation 9, 9.3

Addiction 7.4, 9, 32.2, 34, 34.2, 34.4, 41.3, 44, 47.2, 49.3, 49.5, M47, M147, M167, T124, T172, T175, T193

Addiction circuitry 34.5, M141, W190

Addiction phenotypes 39.1, T195, W161, W181

Adenosine signaling W185

Adenosine triphosphate (ATP) 54.3

ADHD 12, 12.2, M27, T13, W25, W37

Adjunctive therapy M86

ADNI W103

Adolescence 13, 23.3, 39.2, 39.3, M107, M183, T14, T76, T85, T114, W34

Adolescence—critical period 39, M119

Adolescent 12.4, 39.4, M177, T11

Adolescent alcohol M178

Adolescent alcohol exposure 41

Adolescent anxiety 39.4, T164

Adolescent brain cognitive development study T198

Adolescent depression 13.3, M35, M61, M65, T26

Adolescent development M26

Adolescent PTSD M12

Adolescent stress W80

Adolescents M25, M27

Adult hippocampal neurogenesis T29

adverse childhood experiences (ACE) 13.4

Adversity 34

Aerobic exercise 12.4, W169

Affect 44

Affective disorders T21

Affective neuroscience W11

African Americans T10

Ageing 20.2, 31, 31.2, T103, T114

Aggression 11, W182

Aggressive behavior 28

Aging 4, 31.3, T64, T186, W2, W3, W58

Air pollution T77

Alcohol 7.4, 41.2, M152, M167, M173, M186, T72, T161, T176, T179, T181, T188, T194, W146, W165, W172

Alcohol relapse treatment 7.2, 41, M176

Alcohol and substance use disorders 7.3, M160, M176, M191, M192, T42, T164, T172, T195, W181, W182

Alcohol consumption 7.2, 41.5, M178

Alcohol dependence M149

Alcohol drinking 41, M145, M165, T194, W168

Alcohol sensitivity W174

Alcohol use disorder 7, 7.5, 41.4, M149, M159, M163, M169, T43, T55, T183, T186, W147, W157, W165

Alcohol use disorder—treatment M173, T42, T46, T185, T190, W151, W180

Alcohol use disorder metabolism reward T177

Alcohol withdrawal T39, W41, W162

Alcoholic liver disease T185

Alcoholism T175, W156

Alcohol-seeking behavior 41

Allopregnanolone 48.5, T190

Alpha T34

Alpha oscillations W116

Alpha-7 nicotinic acetylcholine receptor M178

Alpha-adrenergic T186

Altitude 3, 3.2

Alzheimer’s disease 15, 15.4, T124, T64, W4, W100, W103, W107

AMPA receptors T188

Amphetamine M101, M147, M198, T174, W166

Amygdala 14.5, 38.2, 45.3, M149, T9, T73, T118, W21, W26, W85, W187

Amygdala-hippocampal differences M57

Analgesics M82

Anhedonia 23.5, M56, M77, T158, W97

Animal model 3.2, 4, 46.1, M148, T38

Animal models 40, M85, M195, T105, W29, W105, W177

Animal research T179, W15

Anorexia nervosa M43, T15, T87, T89

Antagonist ligands T49

Anterior cingulate cortex W196

Anterior cingulate cortex (ACC) M131, M163, T67, W26, W68, W193

Anterior insula T16

Antidepressant 5.5, 47.2, M68, M83, M85, T29, W65, W99

Antidepressant response W67

Antidepressant trials W76

Antidepressants M50, M87, W74, W97

Antipsychotic T110, T148

Antipsychotic drug 30.3

Antipsychotic drugs 30, 30.4

Antipsychotic induced weight gain M37

Antipsychotic medication 18

Antipsychotic response M128, W127

Antipsychotic treatment W90

Antipsychotic-induced metabolic dysfunction 30.3

Antipsychotic-induced weight gain T37

Antipsychotic-naïve first-episode schizophrenia 30.2, 42.5

Antipsychotics M112, M114, W128

Anxiety 3.3, 13.2, 23.3, 28.3, 39, M4, M169, T8, T11, T27, T44, T70, T73, T84, T105, T109, T113, W22, W41, W59, W195

Anxiety & PTSD T2, T12, W11, W17

Anxiety circuitry 14.3, M24, T74

Anxiety disorders T6

Anxiety model T28

Apoer2 M87

Apoptosis W54

Arc M6

Arousal 14, 14.2

ASD 26.3, M28, M29, T81

ASD core symptoms T75

Assessment W35

Associative learning T9, T52, T118

Astrocyte 36, 36.5, T51, T64, W152

Astrocyte-neuron interaction T166, W139

Astrocytes M146, T163

Astroglia T90

Astrogliosis 15.2

Attention M40, M198, M201, T57, T156, W4, W53, W152, W195, W196

Attention deficit hyperactivity disorder W51

Atypical antipsychotics M54, T111, W96

Auditory cortex 6.4, T33

Auditory fear conditioning T9, W18, W30

Auditory mismatch negativity T106

Auditory steady-state response M134

Augmentation M83

Autism 26.2, 26.4, M21, M22, M96, T75, W32, W39

Autism behavior inventory T75

Autism spectrum disorder 20.5, 42.3, M23, M31, T11, T78, T197, W26, W101

Autism spectrum disorder and related syndromes M30, T86

Autoantibody T146

Autobiographical memory T200, W85

Autonomic M113

Autonomic nervous system 29.4, 51.3, M14, W88

aV1ation W101

Aversive learning M190

Avoidance M2, M5

Axon guidance molecule genes 39.1

Axons W108

Balloon effort task M126

Balovaptan W101

Bariatric surgery W47

Basal forebrain M155

Basal ganglia 9.4, M101, W190

Basolateral amygdala 48.5, M20, T85, W28

Bayesian inference M199

BDNF M34, M90, T127, W61, W169

BDNF Val66Met W79

Behavior M15, T91, W98

Behavioral flexibility M59, W189

Behavioral genetics W162

Behavioral pharmacology M152, T191, W15, W161

Behavioral phenotyping T105

Behavioral tasks 40, M62

Behavioural neuroscience W15

Belief updating 6.2

BI 1358894 T94

BI 425809 T134, T135

Bifactor M4

Big data T43

Binge drinking T188, W34, W149

Binge eating 9.2

Binge-drinking W182

Bioenergetics 3.2, 54.5

Bioenergetics and insulin resistance 30

Bioinformatics W56

Biological pathway analysis W102

Biomarker 51, M92, T117, W34, W100

Biomarkers 23.4, 51.1, W17

Biomarkers for risk assessment 21, W126

Bipolar depression W90

Bipolar disorder 2.2, 12, 12.3, 12.1, 12.2, 12.4, 25.2, 31, 31.1, 31.2, 31.3, 38.4, 38.5, 45.1, 54.3, 54.4, M54, M58, M60, M64, M67, M71, M124, M200, T92, T97, T103, T110, T141, W54, W58, W72, W87, W90, W125

Bipolar I & II disorder T110, W132

Bipolar I depression T110, W96

Bipolar I disorder W94

Blood pressure W88

Blood-brain-barrier 36.3

BNST M116, M192, T55

Bodily self disturbance 47.4

Body dysmorphic disorder M103

Body mass index M74

Borderline personality disorder M105, T131

Brain 54.5, M16

Brain age 31, T68

Brain aging W5

Brain based markers for depression M91

Brain circuitry M31

Brain connectivity W155

Brain development 2.3, 24.4, 38.2, M30, M31, M33, W133

Brain imaging 12, 42, M19, T76, T87, W47, W67

Brain initiative 19, 19.2

Brain networks 24.1, T59

Brain organoids 52.4

Brain regulation of metabolism 30.4

Brain reward center M148

Brain stress T60

Brain structural connectivity M66, W33

Brain structure M115

Brain ventricular volume M72

Brain-derived neurotrophic factor M20

Brexanolone injection M80, W92

Bumetanide W2

Butyrate W112

Caffeine M27

Calcium imaging 52.3, M102, M146, T19, T119, W19, W139

Cannabidiol M39, M175

Cannabinoids 16, M157, M183, T126

Cannabis M158, M174, M175, T158, T182, W135

Cannabis use T168

Cannabis use disorder M150, M158

Cardiac autonomic tone 3.4

Cardiometabolic risk T152

Cardiovascular disorders 3, 12.4

Cardiovascular physiology W130

Cariprazine M164, T113

Catatonia 45.2, 45.3

Category learning T22

Causal modeling T43

CB2 W38

CBT T128

Cdk5 W7

Cell adhesion molecules T124

Centanafadine W51

Central amygdala M5, M141

Central autonomic network 3.4

Central nucleus of the amygdala M176

Cerebellum M193

Cerebral blood flow W32

c-Fos M6, M44, W22

Chemogenetics 32.2, T194

Chemotherapy-induced peripheral neuropathy T125

Child abuse and neglect M12

Child and adolescent psychiatry 2.3

Child psychopharmacology T198, W35

Childhood trauma 38.2, 51, 51.2, M55, T183

Children 12.3, T12, T79

Children and adolescents 5.3, 38, W35

Choline T122

Cholinergic system W3

Choroid plexus 36, 36.2, T15

CHRNA5 W53

Chronic pain 27, 27.3, M99, T122, W40

Chronic pain treatment W40

Chronic social defeat M77, T18, T115

Chronic stress M94, T17, T85, W66, W99, W115

Chronic unpredictable mild stress W7

Chrono-pharmacology W94

Circadian M106

Circadian rhythms 37.4, 49, 49.5, T159, W54, W94, W125, W163

Circuit T30

Circuit optogenetics 14, 32, 32.2, W18, W190

Circuit-function M100

Circuitry-based approach T17

Circulating mitochondrial DNA 51.3, 54.5, T82

Citalopram M11

Classification 42.3, W50

Claustrum T62

Clinical development M110

Clinical heterogeneity 2.4

Clinical high risk for psychosis 8, W117

Clinical high risk state for psychosis 30.2, W120

Clinical high-risk of psychosis 21, M132

Clinical interventions M36

Clinical neurobiology T172, T195

Clinical psychiatry 17

Clinical subtypes T89

Clinical transition 53

Clinical trial 28.3, M58, M152, W10, W23, W60, W113

Clinical trial design T46

Closed-loop control 19

Closed-loop deep brain stimulation 9.2, 19.5, 46.4

Clozapine M114

Cluster analysis M172

Cluster headache 47.5

CNS depressant drugs M127

CNV T81

Cocaine 36.5, 49.4, M16, M164, M185, T48, T165, T173, T174, W176, W187

Cocaine addiction M151, M154, M156, T180, W142, W145

Cocaine seeking 10.4, W143, W167, W183

Cocaine self-administration M146, T149, T163, T184, W175

Cocaine self-administration and reinstatement 52.2, M157, W167, W169

Cocaine sex differences T163

Cocaine use disorder 25.2

Cognition 24, 44, M40, M113, M182, T35, T65, T122, T157, W116, W123, W154

Cognitive T20

Cognitive control 9.3, W196

Cognitive decline M94

Cognitive deficits 21

Cognitive development 36.4

Cognitive flexibility 9, M155, M195, T80, W200

Cognitive functioning M114, W113

Cognitive impairment M58, T134

Cognitive impairments T138

Cognitive impairment W174

Cognitive neuroscience 6, T80

Cognitive remediation M134

Cognitive training M157, T6

Cognitive/emotional task performance 13.3

Collaborative cross and diversity outbred mice W163

Combat PTSD M7, M9, T72

Common deletion 54.2

Common SNPs T23

Common variant T36

Communication barriers M22

Comorbidity 17, 31, 31.2

Complement factor C4 43, 43.4, 43.5

Complex I activity 54.2

Compulsion 41.2, M104

Compulsive behavior T188

Compulsive eating W24

Compulsive models of drug use M145

Computational modeling T21, T22

Computational modelling 6.5

Computational models of decision-making 41.3

Computational neuroscience 6, W69

Computational psychiatry M10, W70

Computational reinforcement learning model 39.3

Conditioned fear memory M169

Conditioned place preference M147, W145

Connectivity 43.2, M122

Consciousness T58

Context M177

Contextual cue T3

Contextual fear W30

Continuous performance task W115

Coping 31.1, 34.4

Copy number variants 2

Cortical circuit function 42.3, 45.2, W138

Cortical development 24.1

Cortical excitability M35, M93

Cortical excitation-inihibition balance W93

Cortical GABA T155

Cortical inhibition M93, T153

Cortical plasticity T34

Cortical thickness M159, T102, T133

Corticolimbic W157

Corticospinal tract W170

Corticosterone W79

Corticostriatal networks 9

Cortico-striatal plasticity 48.4

Corticotropin-releasing factor (CRF) M138, T17, W187

Cortisol 27, T7, W165

Cortisol response to stress T96, W156

Court-involved youth M36

COVID-19 17, 33, 50, M17, M181, M197, T159, W12, W43

Craving 36.2, M173, T44

Creatine M124

Creatine kinase 54.3

Creativity W37

CRF W149

CRH 34.3, M162, W28

CRISPR screens 20.4

CRISPR/Cas9 20, 20.5, W148

CRISPR/dCas9 W7

Cross species 34

Cross-species translation 22

CRP T72

Cue reactivity M156, M164, T173, T184

Cue reinstatement T187

Cue-exposure T2

Curriculum W44

Cyclooxygenase 15.5

CYP2C19 T100

CYP2D6 T100

Cytochrome P450s T100

Cytokines W129

D1 dopamine receptors W140, W159, W166

D2 dopamine receptor 10.4, T91, W140

D3 receptor T191

D3 receptor partial agonist M164

Dabigatran T94

Daridorexant M137

Data fusion T1

Daytime functioning M137

DBS 9.4

Decision making M16, W192, W193

Deep brain stimulation 9.1, 46, 46.1, 46.2, 46.3, W49, W83

Deep sequencing 2

Default mode network (DMN) 13.4, T62, T200

Defensive and motivated behaviors 27.2, W21

Delay discounting T44

Delta 6.4

Delta opioid receptors 32.5

Delusions M129

Dementia 4, M129, T150

Dendrites M107, W108

Dendritic morphogenesis M193

Dentate gyrus M59

Dependence W150

Depression 2.1, 3.3, 15.3, 19.5, 23.5, 32.3, 36.3, 37, 37.2, 38.4, 38.5, 45.1, 46, 48, 49.3, M17, M55, M62, M63, M68, M69, M71, M72, M78, M79, M83, M131, M200, T20, T29, T92, T98, T101, T102, T107, T113, W27, W50, W63, W64, W66, W75, W83, W86, W87, W88, W89, W97, W99, W199

Depression and anxiety 23, M161, T56, W72

Depression inflammation M92

Depressive symptoms T148

Depressive-like behavior T105

Desmosterol T117

Devaluation M135

Development M32, W30

Developmental T76

Developmental neuropsychiatric disorders T81

Developmental psychopathology 13, 13.1

Developmental trajectory 51.3, T82, W159

Diabetes 23.2

Diabetic peripheral neuropathy T125

Diagnosis W87, W90

Diagnostic prediction 26.4

Dietary supplement W113

Diffusion tensor imaging (DTI) 12.2

Diffusion tractography 46.2

Diffusion weighted imaging 45, T144, W33

Digital phenotyping W36

Dimensional child psychopathology W31

Discrimination 52.1, W27

Disorders of glutamate M124

Distress intolerance M160

Diverse animal models W69

Diversity 1, 35

DLPFC W109

DNA M120

DNA methylation M18, T33, W58

DNA sequencing 2.2

Dopamine 5.2, 6.3, 19.3, 27, 27.2, 30.3, 34.5, M1, M16, M47, M51, M58, M101, M127, M155, M180, M184, M186, M198, T52, T63, T113, T147, T158, T189, W2, W45, W173, W176, W189

Dopamine (D2, D3) receptors 30.3, M184, W166, W171

Dopamine and serotonin 45.1

Dopamine D3 receptors W178

Dopamine D4 receptor T49

Dopamine receptor type 2-expressing striatal medium spiny neuron M201

Dopamine release 52.2

Dopamine3 receptors 52, 52.2

Dopamine-deficient mice M98

Dorsal Hippocampus T65

Dorsal raphe M180

Dorsal striatum T63, W41, W45, W139

Dorsolateral prefrontal cortex T133

Dose response W146

DREADD 49.3

DREADDs W141, W149

Drosophila T181

Drug abuse 39

Drug addiction 49, M179, T48, T162, W176

Drug cues M154, W186

Drug development 21

Drug discovery—new approaches M31

Drug discovery/development T124

Drug discrimination W51

Drug relapse M142, T50, T196

Drug self-administration M142

D-serine M118

DTI M46, M112, T1

Dual orexin receptor antagonist M137, W134, W150

Duration of untreated psychosis T144

Dynamic connectivity 42.2, M103

Dynamic functional connectivity 42.3

Dynamic neural modeling 19.5

Dynamical systems W136

Dynamics M122

Dysregulation T141

Early adolescence 24.4

Early childhood 12.1

Early life adversity M162, T123, W28

Early life stress 23.4, 34.3, M25, M48, M52, M71, M184, M194, T77, T178, W29, W38, W142, W195

Early parental loss T123

Early psychosis M109, M123

Early rearing T83

Eating disorders T88

Ecological momentary assessment T159, W36, W43, W117, W132

Education and training 33, W44

EEG 26, 47.4, T25, T34, T58

EEG biomarkers 6.5, 13.1, 26.2, M7, M196, M198, W4, W93, W116

EEG/ERP electrophysiology M195, T106, W195

EEG-fMRI W136

Efficacy and safety M110

Effort based decision making task T19, W193

Electrical field modeling W10

Electrochemistry M171

Electroconvulsive therapy M78, T92, T104

Electroencephalography T135, W100

Electron microscopy T147

Electronic cigarette (e-cigarette) M181

Electrophysiology 9.1, 49.4, W18, W135

Emotion circuitry T88

Emotion modulation M105, W65

Emotion perception T57

Emotion processing W65

Emotion regulation M60, W191

Emotional dysregulation 31.1

Emotional memory 13.3

Emotional regulation 31, 38, M197

Emotional stress T98

Empathy W158

Endocannabinoid system M19, M180, T132, W172

Endocannabinoids M188

Endogenous opioids 10.1, 10.3, T54

Endogenous retrovirus 25.3

Engram 52, M6, M42

Enkephalin 10.3, 10.4

Entropy T86

Environmental enrichment W56

Epidemiology 2.4, M68

Epigenetic 32.3, 52, 52.1, W142, W180

Epigenetic modification M149

Epigenetic regulation 32

Epigenetics 25.4, M15, M47, M52, M76, M121, T33, T162, T164, T165, T176

Epigenome wide association studies T176

Epilepsy M40, W105

ERK M90

ER-β M166

Escitalopram T24, W93

Esketamine M81

Esketamine nasal spray T93, T95, W62

Estradiol W81

Estrogen receptor M51

Estrogen synthesis T15

Estrous T187

Ethanol W139, W179

Ethics 16

Ethinyl estradiol M166

Event-related potentials M158, T57, T80, W119

EWAS W103

Excitation-inhibition balance T132, W122

Excitatory and inhibitory imbalance hypothesis M93

Excitatory synapses 52.4

Executive function 3.3, T195

Exome sequencing 2.2

Experimental design T20

Experimental medicine 41.5, W100

Explore-exploit dilemma W192

Exposure therapy T128

Exposure-response M129

Externalizing behavior T79

Externalizing disorders 13.1

Extinction T162

Extinction learning W183

Extinction recall 38.2

Extracellular vesicles 51, 51.3

Extrapyramidal symptoms M125

Eye tracking 26, 26.3, T20

Face emotion processing T22

Facial emotional processing T78

Familial risk 38.4, 38.5, M61

Family study 12.1

Fast scan cyclic voltammetry T189

Fatty acids T89

Fear M18, W19

Fear conditioning 36.4, M6, W20, W21

Fear conditioning and extinction T2, T3, T4, T12, W16

Fear extinction 39.2, M86, T14

Fear generalization 52.1, T2

Fear learning M24

Fear-potentiated startle W17

Fecal microbiome transportation M77

Feeding behavior M41, M42

Females 23.2

Fentanyl 10.2, 49.5, M179, T41, T192, W178

Fetal exposures of alcohol and other drugs M11

FFA M117

Fiber photometry 5.2, M40, M186, T52, T127

Fibroblasts W163

First episode psychosis T144, W127

FKBP5 M71, W78

Flanker task M196

Fluoxetine M90, T18

Functional MRI (fMRI) 5.3, 12, 13.2, 27.3, 38.3, 38.5, 41.4, 42.3, 45, 45.3, 47.4, M4, M19, M23, M60, M122, M131, M154, M164, T3, T6, T21, T56, T60, T61, T70, T76, T87, T200, W25, W46, W67, W114, W117, W158, W186, W192, W195, W198

fMRI effective Connectivity M103, T5

fMRI faces paradigm M103

fMRI functional connectivity T62, T78, W173

Focused ultrasound 19.4

Food cues W46

Forced swim test W29

Four-core genotype mouse W179

Fractional amplitude of low frequency fluctuations M61

Fragile X syndrome T80, W23

FreeSurfer M72, T131

Frontolimbic network M14

Frontoparietal network W4

Frontostriatal circuitry W33

Fronto-striatal networks M61

Frustrative non-reward 5.2, 5.3

Functional capacity M114

Functional connectivity M96, W47

Functional magnetic resonance spectroscopy T69

Functional near-infrared spectroscopy T182

Functional neuroimaging M56, W164

Functional variants T23

Functioning W121

G9a W180

GABA 45, M128, T153, T190, W2, W5

GABA neuron M133

GABA-A receptors M28, M75, T199

GABAergic interneurons 48, 48.3, T63, W18, W98

GAD M17

Galanin W144

Gamma 6.4, 24.2

Gamma oscillation 24, M188, W196

GAT-3 T166

Gender differences M74

Gene co-expression networks 37

Gene expression 32, 32.3, 52.1, M45, M148, M200, T16, T60

Gene-by-sex interaction 37.5

Gene-prioritization 20.3

Generalized anxiety disorder T73

Genetic association 25

Genetic association study 2

Genetic human model T13

Genetic risk factor W72

Genetic variability M19

Genetics 2.2, 37.5

Genetics of depression T23

Genome-wide association studies T140

Genomics 2.4, M121, W123, W124

Genotypes T100

Geriatric M78

Ghrelin T179

Glia 3.1

Globus pallidus 9.4, T131, W152

GLT-1 T163

Glucocorticoid receptor W78

Glucocorticoids W80

GluN2B M89

Glutamate 15.3, 43.2, M128, M185, M191, T145, T147, T175, T176, W5, W45

Glutamate GABA M145

Glutamate receptor function M94

Glutamate transporter (EAAT3) M101

Glycine transporter 1 inhibitor T135

Glyoxalase 1 W162

Goal-directed behaviors M135, T63, W193

Gonadal Hormones M48, W179

GPCRs 32.2

GPER1 T193

Graph theory M66, T88

Graph-based analysis W106

Grey matter morphometry M159

Guanfacine W22

Gut microbiome 29.2, 29.3, W130, W167

Gut microbiota W168

Gut-brain axis 7.3

GWAS 2.1, 20.2, 20.3, T174, W31, W102, W123

Habenula 28, 36.2

Habit W152

Habit formation 48.4

Hallucinations 6, 6.3, M129, M130

Hallucinogen W200

Handwriting M125

Harm avoidance 39.4

HCN M50

HDAC5 T162

Headache 32.5, 47.5

HEAL initiative W1

Health disparities 51.1, 51.4, T82, T183

Health promotion W12

Healthy controls M46

Heart rate variability 29.4, M14

Heritability M67, M70, M121

Heroin T40, W188

Heroin self-administration M184

Herpesvirus M97

Heterochromatin 25.3

Hierarchical perceptual inference W122

High fat diet M45

High potency THC M174

Hippocampal function W131

Hippocampal shape W133

Hippocampal subfields T77

Hippocampus 38.2, 38.3, M81, M84, M90, M117, T3, T154, W5, W19, W78, W79, W133, W137

Histone acetylation M149

Homeostatic plasticity M53

Homeostatic synaptic transmission W145

Hopelessness M60, W84

Horizontal pleiotropy 54.2

Housing M177

HPA axis T7, W78, W80

Human genetics M97

Human laboratory study T179

Human neuroimaging 13, T96, T101, T177, T180, T198, W70, W75, W76, W133, W191, W193

Human post-mortem brain 49.5, 54, M120

Human postmortem brain tissue M106

Humans T108

Hybrid PET/MR W166

Hydroxynorketamine T112

Hyperarousal 14.3, M13

Hyperlocomotion M127

Hypocretin 28

Hypothalamic-pituitary-adrenal axis W197

Hypothalamus T17

Ibudilast T42

Illness trajectory M199, T154

Immobility 32.4

Immune biomarkers 51.4, M165, T146

Immune function 3.4

Immune responses 3, 29.4, 51.4

Implicit bias 35

Implicit priming W46

Impulse control 9.2, M47

Impulsivity 9, 11, M46, M173, T8, T83, T169, T178, W52, W154, W186

In vivo calcium imaging 46.1, M104, T53, T54, W183

In vivo microscopy M102

Incentive motivation 10.1, T54, W189

Incentive salience M187, W184, W186

Incubation of drug craving 36.5, M142, M156

Individual differences M187, W70

Individual variation M172

Induced pluripotent stem cells (iPSCs) 20, 52.4

Infancy 13, 13.1, 26, 26.2, 26.3

Infant 26.4, W27

Inference 6

Inflammasome M2, W38

Inflammation 15, 15.3, 15.5, 23, 23.2, 23.3, 23.4, 23.5, 30, 30.2, 36.3, M38, T64, T72, T103, W9, W57, W129, W130

Inflammatory cytokines W81

Inflammatory markers T102

Information encoding M190

Inhibitory control T27

Inhibitory interneurons T126

Insomnia 20.3, 28.1, M137, M139, T97, T99, T116, T157, W92

Instrumental learning 39.3

Insula M115, M163, W117

Insular cortex T130

Insulin 30.3, W45

Insulin resistance 30.4, M74

Intergenerational depression M59

Interleukin-8 T24

Internal capsule 46.1

Internalizing behavior 13.1, T79

Internalizing disorders T8

Internet of things W48

Internet survey W160

Interneuron 24.2, 48.2

Interoception T73

Interpretation bias T22

Intracortical myelin W110, W118

Intracranial self-stimulation T47

Intravenous drug self-administration T48, T187, W178

Intrinsic excitability W184

Intrinsic functional connectivity W67

Intrinsic neural timescale W122

Ion channels M49, T52

iPSC W54

Irritability 5.3, 5.5, M4, T27, W199

Irritability/Aggression 5, 5.2, 5.4, 28.2, W50

IV—ketamine W88, W95

Juvenile critical period 24.3

Juvenile social isolation M1

Kappa agonist W180

Kappa opioid receptor antagonist T47

Kappa opioid receptors T171, T189, W157

Ketamine 16, 41.5, 47.3, M55, M57, M82, M86, M87, M130, T18, T112, T114, T115, W19

Ketogenic diet W151

Ketorolac M82

Kinases T39

Kynurenic acid T160

Kynurenine pathway M64, T160

Kynurenines 15.3

L1 retrotransposons 25.2

Language delay T121

Large scale networks 45

Late life depression W95

Late-life depression W71

Latent factor analysis T27, T61

Lateral habenula 28.2, M192

Lateral hypothalamus M5

Lateral inhibition T138

Lateral orbitofrontal cortex M104, M135

Lateral septum M20, M43

Learning M16

Learning and memory M42, M95, W5, W194

Learning theory T2

Lemborexant M139, T157

Leptin M74

Lesion W75

Leukocyte telomere length M38

Lifetime stress 29, T82

Limbic brain circuitry 37

Liquid chromatography/mass spectrometry 10.3, M171

Lithium M38, W54

Lithium response W94

Liver brain axis T176

Local field potentials W49

Locus coeruleus 49.3, T173

Long access self-administration T47

Long noncoding RNA 37.2

Long-acting injectable M125

Longitudinal W34

Longitudinal analysis M9, M117

Longitudinal imaging 38.3

Longitudinal MRI M81

Longitudinal studies 38

Longitudinal study 14.4, M199

Long-term depression W190

Long-term potentiation 32.4, T34

Loss W56

LSD 47.3, W49

LSD microdosing T108, W61

M1 and M4 muscarinic receptors M110

Machine learning M100, M121, T30, T59, T181, W49, W71, W155

Machine learning classification 42.5, M67

Magnesium W2

Magnetic resonance imaging 47, W137

Magnetic resonance spectroscopy M21, T67, T143, T145

Magnetic seizure therapy T25, T92

Major depression 37.5, 46.4, M54, W82

Major depressive disorder (MDD) 3.4, 5.5, M56, M57, M74, M92, M93, T23, T24, T25, T92, T93, T94, T95, T104, T117, W57, W59, W60, W67, W68, W70, W74, W199

Major depressive episode 15, 15.2

Mania 38.5, W50

Marijuana M158

Maternal behavior M15, W158

Maternal brain W158

Maternal depression 29.3, T167

Maternal immune activation 25.4

MATRICS consensus cognition battery (MCCB) T137

Matrix metalloproteinase-9 (MMP-9) M144, W14, W137

MCH neurons 49.4

MDD 2

MDMA W6

MDPV self-administration W175

MeCP2 W102

Medial orbitofrontal cortex T53

Medial prefrontal cortex 14.2, 24, 24.1, 24.3, 48.3, M42, T40, T65, T85, T156, W140

Medial septum M155

Medication adherence 18

Medication assisted treatment 11

Medication development 7.3

Medio-dorsal thalamus T53

Medium spiny neuron M49, M146, M150, M190, T41, W183

Memantine W100

Memory 36.4, W104

Memory and learning M143, T66

Memory encoding and retrieval W18

Memory reconsolidation 41.5, W187

Mendelian randomization 54.2

Menopause 3.3

Mental disorders W42

Mesocorticolimbic system T87

Mesolimbic reward circuitry 34.5, T51, W194

Meta-analysis 42.4, M64, T37, T143, T197, W86

Metabolic biomarker T177

Metabolic defect W129

Metabolism 23, 23.4, 23.5, T159, W167

Metabolomics 7.4, 29.3, M168, W168

Metabotropic glutamate receptor 5 (mglu5) T175

Methamphetamine M161

Methods 1

mGlu receptors 48.3

mGlu5 M191

mGlu5-NAM M182

mGluR5 receptors T127, W40

Mice 49.2

Microaggression 35

Microbiome 29, 51.4, M168

Microbiota-gut-brain axis M77

Microglia 29.2, M30, M33, M34, T64, T120

Microglia engulfment 43.4, W159

Microglia priming M76

Microglial activation 15.2

Microresistance 35

MicroRNA 39.1, T131, T141

Mifepristone 7.5

Migraine 47.5

Mild traumatic brain injury M7

Mindfulness M25

Mineralocorticoid receptor M167, W78

Miniscope 52, T119

Mismatch negativity 6.5

Mitochondria 23.3, 54, 54.2, 54.5, M33, M45, T112, W57

Mitochondrial DNA 54, W126

Mitochondrial dynamics W57

Mitophagy W57

Mobile DNA 25

Molecular genetics 2.1, M37, T124

Molecular imaging 19.3

Monetary incentive delay task M63, T61

Monetary reward M8, T87, W172

Monoamines M47

Monocytes W108

Monogamy T119

Mood 28, M70, T108

Mood and anxiety disorders 3, 38, T98, T107

Mood disorders 42.2, 44, M64, M83, M88, M89, T16

Morphometry M115

Motivation M48, M62, M180, W185, W194

Motor activity M67

Motor behavior T86

Motor evoked potentials T199

Mouse T81

Mouse behavior M127

Mouse genetics 32.3

mPFC M95, M100, T162

MRI 26.4, 42, 45.4, M66, T1, T186, W64

MRS W107

MRSI M128

Multimodal data 42.5

Multimodal neuroimaging T1, W121, W151

Multi-omics M168, W8, W56

Multiplex families 2.2

Multi-site MRI 31.3

Mu-opioid receptors 32.5, T28, T50, T171

Muscarinic acetylcholine receptor M88, W53

Muscarinic receptors T150

Myelination M30

Myosin M143

N,N-dimethyltryptamine (DMT) T58

N100 W119

N-acetylaspartate T122

N-acetylcysteine T145

NAD+ and NADH W98

Naltrexone T151

Nanoparticles 19.4

Natural dietary product W160

Natural language processing (NLP) W120

Natural setting T58

N-back T182

Negative emotionality T195

Negative reinforcement 34.4

Negative symptoms 21, M108, T136, W121, W129

Neonates 13.2

Network based statistic (NBS) T31

Neural circuitry 5

Neural circuit and animal behavior 10.4, 52.1, 52.3, M44, T51

Neural circuits 34.2, 41.2, M136

Neural decoding 19.5

Neural modelling W69

Neural network connectivity W69

Neural oscillations 24.1

Neural predictors T30, T88

Neurocircuitry W149

Neurocircuits 10, 19.2

Neurodevelopment 20.4, 38, 41.3, 45.4, 55, T59

Neurodevelopmental and behavioral deficits M11

Neurodevelopmental disorders 2, 26, W32, W108

Neuroeconomics W114

Neuroendocrine T71

Neuroepigenetic editing W7

Neuroepithelium 36

Neurofibromatosis type 1 M29

Neurogenetics 2.3

Neuroimaging 26, W34

Neuroimaging biomarkers 30

Neuroimmune T120

Neuroimmune interaction T180

Neuroimmune mechanisms M169, M185, T42, T45, T184, W167

Neuroinflammation 15.4, M99, T24, T145

Neuromelanin M8

Neuromelanin-sensitive MRI M13, T173, W153

Neurometabolism W136

Neuromodulation 19, 19.5

Neuromodulators 19.3

Neuronal ensemble 52, 52.1, 52.3, W143

Neuronal epigenome 25.3

Neuronal tracing T74, W190

Neuropathic pain 32, 32.3, M97, M148, T125

Neuropeptides M176, T118

Neuropharmacology 48.3, W88

Neurophysiology 46.3

Neuroplasticity 47, 47.2, 51.2, T121, W61, W107

Neuroplasticity hypothesis M93

Neuropsychiatric disorders [schizophrenia, Parkinson’s disease, major depressive disorder] 37.4, 46.3

Neuropsychology M78

Neuropsychopharmacology 19.4, 41.4

Neurosteroids T190

Neurostimulation 19

Neurotechnology 19.2

Neurotensin M43, T118

Next generation sequencing M148

N-glycosylation T36

Nicotine 36.2, M39, M153, M181, M183, W177

Nicotine addiction M151, W148

Nicotine demand M166

Nicotine dependence M170, W138

Nicotine vapor M170

Nicotine withdrawal W171

Nicotinic acetylcholine receptors W53

NMDA antagonists M130

NMDA glutamate receptors T40

NMDA Receptor M53, M118, M133, T199

NMDA receptor antagonist T106

NMDA receptors T146

NMDA receptors, MMN, ERP, auditory, training 6.4

NMDAR hypofunction M118

Non pharmacological interventions M79, T133

Non-coding RNA W147

Nonhuman primate model T83

Nonhuman primate models W168

Non-invasive brain stimulation T133

Non-invasive neuromodulation W170

Non-suicidal self-injurious behavior M65, T140

Non-suicidal self-injury (NSSI) T83

Noradrenaline M13, T156

Noradrenergic W144

Norepinephrine 14.2, T173, W22

Nosology 42.2

Novel antidepressant T65

Novel therapeutics 53, T185

Novelty response W22

Npas4 W145

NR2B receptor M89

NREM EEG gamma power M132

Nuclear factor kappa B T184

Nucleus accumbens 5.2, 9.2, 10, 10.2, 10.3, 34.3, 36.5, M3, M49, M144, M150, M162, M186, M188, M201, T41, T107, T119, T127, T165, T178, W14, W28, W55, W66, W145, W169, W183, W184, W185, W188, W189

Nucleus accumbens core W140

Nucleus accumbens shell 10.1, M146, T54

Nucleus reuniens W13

Number needed to treat W91

Obesity M37, T68, W46

Obsessive-compulsive disorder (OCD) 45.3, 46, 46.1, 46.2, M101, M102, M163, T31, T128, T129

Obsessive-compulsive spectrum disorders (OCDS) T127

Occipital pole M117

OCD T130

Olanzapine M111

Oleanolic acid acrylate T28

Oligodendrocytes 36

Omega-3 fatty acids W197

Operant behavior T181, T191

Opiate addiction W170

Opioid M99

Opioid abuse M172, M189, T192, W40

Opioid addiction 9.1, 34.3, 49.2, M144, M162, T38, T44, T50, T170, T171, T196, W140, W144, W159, W161, W188

Opioid dependence M148, T38

Opioid epidemic 50

Opioid epidemic—novel approaches W164

Opioid peptides M171

Opioid receptors T151

Opioid side-effects T45

Opioid use disorder T45, W153, W155, W158, W160, W164

Opioid withdrawal T171, W144

Opioids 7.4, 10, 32, 49.5, T48, W178

Opto-chemogenetics 52.2

Optogenetics 32.4, 41.2, M40, M100, M187, W20, W48

Orbitofrontal cortex (OFC) M59, T53, T130, T196, W141

Orexin 28.1, 28.3, T188

Orexin receptor antagonist 28, 28.2, W60

Orexin system W134

Organic cation transporters M147

Oscillation 6.4

Oscillations 48.5

Oxidative phosphorylation 54.4

Oxidative stress T67, W58

Oxycodone 9.1, 32.3, M142, T47, T187

Oxytocin W24, W26

Oxytocin and addiction 7.2

Oxytocin receptor 7.2

PACAP 32.5, M138

Pain 32.2, 32.5, 53, M175, T161, W1, W199

Pain analgesia M99, T45

Pain therapeutics W170

Paliperidone palmitate long-acting injection W110

Paranoia 6, 6.2

Paraventricular nucleus of the thalamus W134

Parenting distress M59, T167

Parkinsonism 45.2, 45.4

Parkinson’s disease 9.4, 46, M98

Partial agonist ligands T49

Parvalbumin 24.2, 48.2

Parvalbumin fast-spiking GABAergic interneurons 48.4, 48.5, M118

Patch foraging W153

Pathways T142

Patient outcomes W62, W86

Patient reported outcomes M137, T95

Pavlovian bias 39.3

Pavlovian conditioning M19, T9, T53, W184

Pediatric T128

Pediatric irritability W36

Pediatric PTSD 38.3

Pediatrics 38.4, W35

Perceived stress M173

Perceptual reasoning T77

Periaqueductal grey (PAG) 32.4

Perinatal T111

Perinatal stress 29, 29.4, M11

Perineuronal nets 36.4

Peripheral biomarker T90

Persistent avoidance T130

Personality T76

Personalized medicine 12.3, 46.4, 47.3

Positron emission tomography (PET) 15.2, 15.5, 43.3, M191, W157

Positron emission tomography (PET) Imaging 15.4, 43.5, T7, W32, W96, W165, W171, W173

PET imaging study M73, W40

PharmacoBOLD M105

Pharmacogenetics W73

Pharmacoepidemiology W73

Pharmacogenetics M69

Pharmacogenomic-guided treatment recommendations W73, W74

Pharmacogenomics T100

Pharmacologically-based nomenclature 18

Pharmacology 18

Pharmacotherapy 41.4, M148, T38

Phosphodiesterase-4 (PDE4) W104

Phosphoproteomics T39, W8

Phosphorylation W146

Physical activity W43

Physician-scientist 33

Physiologic biomarkers M91

Pimavanserin M129, T136, W59

Place cell W131

Placebo response M63, W76

Placebo-controlled trial W128

Plasma membrane monoamine transporter W176

Plasma psilocin W77

Pleiotropy analysis W123

Polydrug use M143

Polygenic risk scores W31, W32

Polygenic scores T35

Polysomnography T26, T158, W96

Positive emotion W84

Postmortem W125

Postmortem brain tissue 37.3, 54.4, T33, T179, W124

Postmortem human brain 37.4

Postpartum anxiety M80

Postpartum depression M80, T109, W80, W81, W91, W92

Prader Willi syndrome W24

Prairie vole T119

Pramipexole M56

Prebiotic treatment in schizophrenia W112

Precision medicine for mood and anxiety disorders 29.4

Precision medicine for mood disorders 29, 55

Precision psychiatry M56

Preclinical models and endpoints W1

Prediction 26.3

Predictive coding 6.2, T155

Predictive models 20.2

Predictor of treatment response W71

Prefrontal 24.2

Prefrontal circuit M119, T19

Prefrontal circuit maturation 24, M12

Prefrontal cortex 41.2, M34, M90, M135, T120, T182, W21, W30, W53, W63, W192

Pregnancy 51.2, T111, W27, W98

Prelimbic cortex M135, M160, T130

Premenstrual dysphoric disorder M73, M75

Prenatal drug exposure M161, W159

Prenatal stress 29.2

Prescription opioids M142, T38

Presymptomatic 26.4

Presynaptic mRNA T66

Probabilistic reversal learning 41.3, M126, M195, W200

Prodromal schizophrenia W119

Prodrome 12

Progesterone T4

Pro-inflammatory cytokines T123, W82

Proof of concept M25

Proopiomelanocortin neurons T194

Prophylactic M178

Propranolol M6

Protein aggregation T32

Proteomics 41.3, 54.5, W124, W146

Psilocybin 47.5, M41, M140, T46, T129, W77, W97

Psychedelic medicine 47, M140, T46

Psychedelics 16, 47.2, 47.3, 47.4, 47.5, M41, M85, T62, T108, T129, W49, W99

PsychENCODE 25.3

Psychiatric disease 25

Psychiatric education 33, W44

Psychiatric genetics 5.4, 20, T174

Psychological effects T58

Psychological pain T99

Psychomotor speed W174

Psychomotor symptoms 45.1

Psychoneuroimmunology T180

Psychopharmacology treatment guidelines W90

Psychophysiology 14.4, W17

Psychosis 6.2, 30.4, 42.2, 54, M113, M115, M131, T132, T146, T152, W35, W116, W122, W137, W198

Psychosis continuum 6.2

Psychosis spectrum M122

Psychosis spectrum disorders 47.3

Psychostimulants W25

Psychotherapy T5, T167

Psychotic depression W128

Psychotic disorders 42

Psychotic-like experiences M98

Psychotropic medications 18, T139, W42

Post traumatic stress disorder (PTSD) 2, 2.1, 14.3, 14.4, 14.5, 23.5, 37.3, 51, 51.1, M2, M3, M10, M13, M14, M17, T3, T4, T5, T7, T72, T167, W9, W10, W12, W13, W14, W16, W63, W134

Pubertal stress M85, W89

Puberty T71

Public health T168

Punishment T170

Pupillometry 14

Pyramidal neuron 54.4

qFISH M38

QIDS-SR16 W68

Quality of life T183

Quantitative EEG M140

Quantitative electroencephalography (qEEG) M182

Quetiapine M98, T24

R-(-)-ketamine T115

Racial differences W82

Racism 51, 51.1, T10

Raclopride M63, M96

Randomized clinical trial T5, T136

Randomized controlled trial 7.5

Rapid antidepressant M53, M84

Rapid mood screener W87

Rapid-acting antidepressant T115

Ras/MAPK pathway T13

RASopathies M29

Rats W20

RCT M69

Real-time fMRI W64

Real-time fMRI neurofeedback M25, W84, W85, W194

Receptor binding T28

Receptor internalization, trafficking W166

Recidivism M36

Recordings W20

Recovery 22

Redox dysregulation 54.3

Reelin M87

Registry T111

Regulatory policy 16

Regulatory variation 20.4

Reinforcement M188

Reinforcement learning 44, M16, W192

Reinforcement learning modelling M195

Reinforcement-based decision-making T191

Reinstatement M166, M177, T170

Relapse T29

REM sleep 49.4, M138, M159, T160

Remission 38.3

Remote memory W30

Repetitive behavior W24

Repetitive transcranial magnetic stimulation (rTMS) M21, M35, M91, T90, T199, W63, W86

Reproduction M48

Research domain criteria (RDoC) 55, T59

Residency training 33

Residential treatment 39.4

Resilience 34.4, M197

Resiliency M172

Respiration T112

Resting state 38.5, W116

Resting state functional connectivity 12.2, 13.4, M123, M130, T13, T56, T59, W25, W106, W138

Resting state intrinsic connectivity T55

Resting-state fMRI 6.5, 45.2, M65, M191, T5, T31, T128, W39, W77, W120, W127

Retina 49.3

Retrotransposon 25.4

Reversal learning T80

Reward 27, 27.1, 49, M63, M153, M158, T76, W20, W28, W156

Reward and aversion M145

Reward anticipation T177

Reward circuitry 34, 34.3, 46, M162, W143

Reward functioning M61

Reward learning M161, M190

Reward memory W97

Reward neural circuitry 38.5, W67

Reward sensitivity W52

Reward-based decision-making 39.3, M62, T191, W153

Reward-seeking behavior M84, W115, W139

Rhesus M18

Risk and resilience 38.5, 39.1, M9, M11, W121

Risk calculator 12.1, 12.3

Risk taking behaviors W141

RNA splicing W147

RNAseq 10, 10.2, 49.4, T16, T18, T41, T107, T142, T156, W8, W56, W79

Rodent models 6.3, M62, T47, W11

Rosuvastatin T94

Rumination T56

Safety 39.2

Salience 27.1

Salience network 13.4, T31

Salvinorin A T62

Samidorphan M111, T151

Schizoaffective disorder W112

Schizophrenia (SCZ) 2.2, 6.3, 25.2, 37, 42.3, 43, 43.4, 45.1, 45.2, 45.3, 45.4, 48.2, 54.3, 54.4, M64, M106, M107, M108, M111, M114, M117, M118, M120, M122, M124, M125, M126, M128, M134, M136, M200, T25, T32, T33, T34, T36, T104, T134, T135, T136, T138, T139, T141, T143, T145, T146, T148, T150, T153, T154, T160, W110, W112, W114, W118, W121, W122, W123, W124, W125, W126, W129, W133, W134, W136, W138

Schizophrenia and bipolar disorders 37.5, T140

Schizophrenia negative symptoms 42.4

Schizophrenia novel treatment 43.2, M71, T133, T137, T142, W130

Schizophrenia prodrome 8

Schizophrenia spectrum disorders 30, T197

Schizophrenia subtypes 43.5, M116, T32

Schizophrenia, antipsychotics 43.3, M110, T35, T37

Schizophrenia, synaptic aberrations 6.5, 48, M200

Schizophrenia; functional capacity; technology W132

Schizophrenia; technology 42.4

Schizophrenia-like behavior W135

Scopolamine M88

Screening W87

Seahorse T112

Self-administration 41.4, M177, T50, W51, W148, W177, W187

Self-regulation W194

Seltorexant W60

Sensorimotor M23, T86

Septum 36.2

Sequencing M120

Serious mental illness 4

Serotonin 3.2, M180, T91, T189, W6, W52, W89

Serotonin 1b receptor W52

Serotonin 5-HT2A receptor 47.4, M85, W200

Serotonin 5-HT2C receptor M192

Serotonin transporter M73

Serotonin transporter genotype T83

SERT W6

Serum levels M92

Set shifting 24.2

Severe major depressive disorder W62

Sex 23.3

Sex chromosomes W179

Sex differences 3, 3.1, 3.4, 23, 24.4, 27, 27.1, 27.2, 27.3, 34, 34.5, 37.2, 37.4, 37.5, M16, M30, M32, M44, M94, M147, M189, T12, T67, T68, T71, T79, T96, T123, T164, T178, T181, T187, T193, W7, W39, W55, W79, W89, W142, W146, W157, W173, W178, W179, W188

Sex hormones 2.1, T67, W142

Sexual dimorphism 34.2, 36.3

SGE-516 T190

Shank3 T40

Shati/Nat8l M95

Short tandem repeat M120

Side effects W42

Sigma-1 receptor T161

Signal detection T169

Sign-tracking M151

Simulated data 42.5

Simulated driving T168

Simultaneous PET-MR M96

Single-cell analysis 51.4

Single-cell RNA sequencing 20.5, 36, W109, W148

Skin conductance response T44, T57, W16

SLC39A8 T36

Sleep 49, M67, M70, M138, M189, T99, T116, T152, T159

Sleep architecture M132, M140

Sleep deprivation T26

Sleep disturbance 49.2, M27, M132, T97

Slow wave sleep M159, T26

Smartphone W48

Smartphone apps W164

Smoking M153, W154

Smoking cessation W177

SMS text messaging M109

SNRI M72

Sociability W41

Social anxiety M8, T71

Social attention T169

Social behavior 24, 24.3, 24.4, 40, M32, M34, M100, M141, T84, T123

Social brain M153

Social cognition T197

Social communication T78

Social defeat 40

Social defeat stress 10.2, M52, M76, T192

Social dominance T91

Social factors and functioning T180

Social functioning 31.1

Social interaction M28, M161

Social isolation 24.3, M34, W43, W115

Social media monitoring W160

Social motivation M51, M96

Social processing T169

Social recognition memory M20, M32

Social rejection M8

Social responsiveness M22

Social withdrawal T107

Socio-economic status M26, T10

Somatic mosaicisms 25.4

Somatostatin 48.2

Speed of processing W118

Sphingosine 1-phosphate receptor T125

Sphingosine-1-phosphate W105

Spironolactone M167

Src family kinases M87

Selective serotonin reuptake inhibitors (SSRIs) M11, M72, T70, W93

SSRT M154

Statistical methods W86

Stem cells T142, W108

Stimulants W37, W173

Strategy switching M155

Stress 23.3, 32.3, 52.1, M70, M86, T120, W19, W27

Stress and anxiety behavior 14.5, M176, W197

Stress and anxiety disorders M11, M116

Stress and depression 3.1, T60

Stress and trauma 23, 23.2, 51.3, M17, M24, T82, W21

Stress coping M197, W13

Stress models 24.4, 34.5, 36.3, W180

Stress reactivity M131, M169, T60, W165

Stress resilience and susceptibility M12, M194, T30

Stress-induced dopamine release T171

Striatal dopamine signaling T63

Striatum 6.3, 9.3, 10.4, M8, M102, T9, T158, W125

Structural and functional connectivity 13.3

Structural MRI 5.4, 45.2, M12, T15, T154, W120

Structural neuroimaging 12.4

Structure of psychopathology 55

Subcallosal cingulate W83

Subcortical shape analysis M26

Subcortical-cortical motor loops 45.1

Subgenual anterior cingulate T16

Substance abuse M123

Substance abuse disorders 22, 39.4, T167, T174

Substance use disorders 50, M3, T48, T169, T178, W186, W199

Substantia nigra T50

SUD-like phenotypes W175

Suicidal behavior M65, T140

Suicidal ideation M65, T93, T95, T99, T140

Suicidality 5, 5.5, M60

Suicide T99, T116, W84

Suicide prediction 5.5

Sulforaphane M22, T137

Susceptibility 34.4

SV2A protein 43.3

Symptom trajectory M9

Synapse T120

Synapse pruning 43.4

Synapses 43.2

Synaptic aberrations 32.3, 48

Synaptic density 43

Synaptic function W99

Synaptic plasticity 10.3, 32.3, 48.3, 52.1, M3, M15, T199

Synchrony T30

Synthetic psychoactive cathinones W175

Systematic review T197

Systemic inflammation W198

Systems biology 29.3

Systems neuroscience 14, W148

TAAR1 M108, T149, W6

Target engagement W26

Task-based functional connectivity T78, W11

TBI T79, W106

TDCS W10

Temperament T84

Temporal discrimination W131

Testosterone T65, T71

Tetrapartite synapse M3, M144

Thalamus 24.3, M130

THC M174

Th-Cre M187

Theta 6.4

Theta burst transcranial magnetic stimulation M10

Theta-burst stimulation M14

Time cell W131

Time-frequency 6.4

Timing M188

TMS T101

TMS-EEG T153, W107

Tobacco smoking W171

Tolerance W174

Top-down W196

Top-down control M119

Touchscreen M196, T156, W115

Training 1

Transcriptome 20.2, T141

Transcriptomics 14.5, 37.3, T66, W8, W109

Transdiagnostic 5, M199, M200, W191

Transforming growth factor beta-1 T115

Transgenerational M15

Transgenerational epigenetic effects M11

Transgenic mice M133, W4, W104, W162

Transgenic models M194

Translating innovation 53

Translational approaches to drug development 7

Translational neuroscience 5, 9.2, 19.2, 22, 28.3, W181

Translational pharmacology M167

Translational research T6, T108

Translatomics W8

Trauma W17

Trauma exposure T1, T69

Traumatic brain injury 15.2

Treatment M79, W160

Treatment adherence M109, W155

Treatment mechanisms 7

Treatment outcome prediction T88, W155

Treatment prediction W70

Treatment resistant depression 3.2, M68, T18, T90, T116, W85

Treatment response 42.5

Treatment-refractory depression W95

Treatment-resistant schizophrenia M112

Treatment-response M55

TRIP8b M50

TrkB M20, W169

Tryptophan catabolites (TRYCAT) M92, T160

TSPO 43, 43.5

TSPO and [11C]PBR-28 PET 43.3, M165, T7, T45

Two-photon calcium imaging T126, T155

Two-photon imaging 14.2

Type 1 corticotropin releasing factor receptor M1

Type-2 diabetes 30.4

Ultra high-risk youth 8

Ultrasonic vocalization W11

Uncertainty W189

Underrepresented 35

V1aduct W101

Vagus nerve M77

Valence 27.1, T118

Validation 40, W1

VANILLA W101

Vaping M179

Vapor W135

Vascular endothelial growth factor T90

Ventral attention network T6, T31

Ventral capsule/ventral striatum 9.3

Ventral hippocampus 39.2, M136, T14, T74, W66

Ventral pallidum 9.1, 52.2, M145, T166

Ventral tegmental area (VTA) 27.2, 32.4, M52, M186, T52

Ventromedial prefrontal cortex T73, W84

Verbal learning T137

Veterans W63, W106

Violence T139

Visual attention M119

Visual cortex 14.5, M119, T126

Visual processing M103

Visuospatial ability T121

Visuospatial working memory T137, T138

vmPFC W10

Voltage-gated calcium channel M193

Voxel-based morphometry (VBM) M163

Vulnerability M172, W66

Vulnerability traits 23.4

White matter fractional anisotropy M46

White matter integrity W9

Whole-brain rodent imaging 7.4, W3

Whole-cell patch clamp recording W184

Whole-genome M120

Wistar Kyoto rat M140

Withdrawal M39, M148, M170, M189, T38

Women’s health T111

Women’s mental health W93

Working memory 48.2, M157, T20, T69, T182

Worry T56

Xanomeline T150

Youth M4, M199

Zebrafish M31, W69

Zuranolone T109, W91

α5-GABAA receptor negative allosteric modulator M84